The activation of primary afferent neurons that innervate the airways leads to homeostatic and defensive reflexes. The anatomic and physiologic characteristics of these afferent fibers do not appear to be static properties but rather appear to change rapidly in response to inflammation. The threshold for activation of airway afferent neurons to various stimuli, for example, is not fixed; these fibers can become sensitized during inflammation. A subset of nociceptive-like (C-fibers) airway afferent neurons not only participates in centrally mediated reflexes but is also thought to release neuropeptides at their peripheral terminals, leading to neurogenic inflammation. An increase in the content of tachykinins is commonly seen in inflamed tissues, and there is accumulating evidence that irritation and inflammation of the airways is associated with the induction of tachykinin synthesis in non-nociceptive airway afferent fibers that under normal conditions do not contain neuropeptides. The release of neuropeptides from the peripheral terminals in the airways and their central terminals in the brain stem may contribute to the symptoms of inflammatory airway diseases. Elevated release of neuropeptides from peripheral terminals may promote local inflammatory responses, and the release of neuropeptides in the brainstem, together with inflammation-induced increases in the excitability of afferent fibers, may culminate in altered visceral autonomic reflex activity, changes in breathing pattern, and cough. Key words: airway inflammation, airway innervation, nerve growth factor, substance P, tachykinins, vagal afferent. — Environ Health Perspect 109(suppl 4):567-571 (2001). http://ehpnet1.niehs.nih.gov/docs/2001/suppl-4/567-571carr/abstract.html

A variety of stimuli including chemicals, extremes in osmolarity, elevated H⁺ ion concentrations as well as mechanical stimuli are sensed by afferent neurons that innervate the airways. These stimuli evoke action potentials at the peripheral terminals of afferent neurons that are conducted to the central nervous system. The central terminals or neuron terminals that excite secondary neurons in the brain stem or spinal cord, leading to homeostatic and defensive reflexes. Reflexes initiated in the airways include sneezing, coughing, changes in autonomic drive, and alterations in the depth and pattern of breathing.

In a number of tissues and organs, the various anatomic and physiologic characteristics of afferent fibers do not appear to be static properties, but rather appear to change rapidly in response to inflammation (1-5). In this overview, literature relevant to inflammation-induced anatomic and physiologic plasticity of airway primary afferent neurons is discussed.

Anatomy and Physiology of Airway Afferent Nerves

There are several subtypes of afferent fibers in the airways (6-8), and it is difficult to devise an unambiguous classification scheme that takes all features of these fibers into account (9). One scheme classifies afferent fibers according to the location of their cell bodies. For example, the nasal mucosa is innervated by sensory neurons whose cell bodies reside in the trigeminal ganglion (10,11), whereas those that innervate the trachea and bronchus have cell bodies residing in inferior (nodose) or superior (jugular) vagal ganglia (12). Although some afferent neurons that innervate the lung have cell bodies that reside in dorsal root ganglia (12,13) few studies have concentrated on the spinal innervation of the airways.

Afferent fibers innervating the airways may also be broadly classified into two physiologic types: those that monitor normal physiologic activity and those activated by potentially damaging noxious stimuli. Afferent fibers that can be activated by mechanical forces occurring during normal respiration include slowly adapting stretch receptors (SARs) and rapidly adapting receptors (RARs). Activation of SARs leads to inhibition of inspiration, relaxation of airway smooth muscle, peripheral vasodilatation, and tachycardia (7,8). Activation of RARs leads to increased inspiratory effort, contraction of airway smooth muscle, and bradycardia (7,8). Afferent fibers activated by noxious stimuli and by mediators associated with tissue damage and inflammation include some thinly myelinated Aδ-fibers and unmyelinated C fibers. Reflexes resulting from activation of these fibers include inhibition of inspiration and expiration (causing an initial apnea followed by rapid shallow breathing), bronchoconstriction, an increase in bronchial blood flow, and bradycardia (8).

In the guinea pig, airway afferent fibers whose cell bodies reside in the nodose ganglia appear to correspond to myelinated fibers that monitor normal physiologic activity. They are exquisitely sensitive to mechanical stimuli but do not respond to a variety of chemical stimuli, including capsaicin and bradykinin (Figure 1) (14). By contrast, the jugular ganglia contain the cell bodies of myelinated Aδ fibers and unmyelinated C fibers. Jugal afferent fibers innervating guinea pig airways resemble the nociceptive fibers of the somatosensory system in that they have relatively high thresholds to mechanical stimuli, but respond vigorously to classic nociceptive fiber-selective stimuli such as capsaicin and bradykinin (Figure 1) (14).

A subset of airway afferent neurons not only participate in centrally mediated reflexes, but are also thought to release neuropeptides at their peripheral terminals. The locally released peptides can activate neurokinin (NK) receptors in a variety of airway tissue and cell types, leading to alterations in bronchomotor tone, mucus secretion, and neurogenic inflammation. The predominant neuropeptides found in this subset of airway afferent fibers are calcitonin gene-related peptide (CGRP) and the tachykinins substance P and NK-A (15). Under normal conditions the tachykinergic innervation to the airways is thought to be derived exclusively from neurons that project nociceptive-like C fibers. In the guinea pig and rat airways, the cell bodies of the vagal afferent fibers that contain tachykinins are C fibers whose cell bodies reside in the jugular ganglia (12,14,16,17).

Inflammation and the Excitability of Afferent Neurons

The threshold of primary afferent neurons to various stimuli is not fixed, but rather can be become sensitized during inflammation (4). Perhaps the most dramatic examples of this sensitization occur when an inflammatory mediator fails to overtly stimulate action potentials, but influences the nerve ending in such a way that the nerve responds to stimuli that were previously subthreshold. This is known to occur following experimental...
arthritis in rats, where afferent neurons that normally fail to respond even to noxious rotation of a rat joint respond to simple flexion following arthritis (18,19). Likewise, afferent fibers insensitive to mechanical distension of the bladder respond to modest distension following inflammation (20). Allergic rhinitis is associated with increased nasal neural responsiveness to stimuli that evoke sneezing, the nasonasal secretory reflex, and axon reflex-mediated plasma extravasation (Figure 2) (21). In the human upper airway subthreshold concentrations of a sensory nerve irritant reach threshold and evoke autonomic and sneezing reflexes when applied during the time of allergic inflammation (22).

Increases in afferent nerve excitability may contribute to the responsiveness of the airway to various bronchoconstrictor stimuli. Airway hyperresponsiveness is a key feature of asthma and is defined as that phenomenon reflected in a substantial increase in the resistance to airflow in response to a bronchoconstrictive stimulus at doses that have little or no effect in the nonasthmatic population. Many mediators found in the inflamed airways of asthmatics may modulate the sensitivity of afferent neurons. This has led to speculation that analogies may be drawn between asthma-associated airway hyperresponsiveness and hyperalgesia (heightened sensitivity to painful stimuli) that often accompanies inflammation in the somatosensory system (23). Most stimuli administered to assess airway hyperresponsiveness, including histamine (24,25), capsaicin (26), bradykinin (27), distilled water (28), and sulfur dioxide (29), cause bronchoconstriction by stimulating primary afferent nerve fibers and initiating central parasympathetic cholinergic reflexes. Experiments in animal models suggest that even the response to a so-called direct smooth muscle spasmogen like methacholine is likely to be mediated in part by a centrally mediated cholinergic reflex (30). It follows, therefore, that an increase in the excitability of the afferent endings associated with inflammation in the airway wall will lead to a heightened reflex bronchoconstriction at a given dose of stimulant and thereby contribute to airway hyperreactivity.

Studies of respiratory viral infections support the hypothesis that the afferent innervation of the lung contributes to certain types of hyperresponsiveness. Respiratory tract viral infections are often associated with exacerbations of asthma and the induction of bronchial hyperresponsiveness in otherwise normal healthy subjects (31-35). The reasons for this association are yet to be resolved and appear to involve multiple mechanisms (36) including increases in the excitability of airway afferent neurons. Empey and co-workers (35) reported that respiratory viral infections cause subjects to develop airway hyperresponsiveness to inhaled histamine. The observation that muscarinic cholinergic agonist atropine prevented this response suggests the exaggerated bronchoconstriction was due to an increase in the excitability of afferent neurons that innervate the airways, leading to enhanced parasympathetic, cholinergic reflex-mediated bronchoconstriction. This is supported by their observation that the threshold concentration of citric acid that produced cough in subjects with viral infections was significantly lower than in control subjects or in subjects after recovery from infection. These observations suggest that respiratory tract viral infections can sensitize the airway afferent fibers that initiate reflex bronchoconstriction and cough.

The mechanisms underlying increases in excitability of nerve endings at the sites of airway inflammation are not known. In an in vitro study on airway nerve endings, the mechanical sensitivity of Aβ-fibers innervating guinea pig isolated trachea from immunologically sensitized animals increased following exposure to the relevant antigen (37). In this model, exposure of the trachea/bronchus to the relevant antigen results in inflammatory mediator release, but does not overtly activate the afferent nerve endings. Rather, antigen challenge increases the excitability of the nerve endings, resulting in a 4-fold decrease in the amount of mechanical force required to activate the nerve fibers (37). In general terms the data available on this subject are compatible with the hypothesis that various
inflammatory mediators bind to receptors on the nerve endings and modulate current flow through various types of ion channels (38). Inflammation-induced changes in the viscoelastic properties of the airway wall may also contribute to increased excitability of afferent nerves (39).

**Inflammation, Tachykinin Levels, and the Density of Afferent Innervation**

An increase in the content of tachykinins is commonly seen in inflamed tissues (1,40–43). With respect to airways the baseline amount of substance P in human nasal lavage was greater in atopic subjects with grass pollen allergy than in healthy nonallergic subjects, and allergic challenge elevated these levels further (44). The concentration of substance P in the sputum of patients with chronic obstructive pulmonary disease or asthma was also greater than that found in the sputum of healthy volunteers (45). Haneef and co-workers, however, found no immunoreactive substance P or CGRP in bronchoalveolar lavage fluid (BALF) of asthmatics or control subjects. However, they did find NK-A, and the levels of this tachykinin were similar in BALF from asthmatics and healthy subjects (46). Lilly and co-workers found significantly less substance P in lung tissue from asthmatics compared with nonasthmatics (47). One possible explanation for these conflicting data may be variable proteolytic breakdown of tachykinins within the airways. An alternative method of assessing the expression of tachykinins may be to quantitate the levels of tachykinin immunoreactivity or mRNA encoding tachykinin precursor peptides in the cell bodies of afferent neurons. This approach has been useful in studies of rodents (see below).

The influence of inflammation on the density of the neuropeptide-containing innervation to the human airways is controversial. Nasal turbinate blood vessels from rhinitic children were more richly innervated with CGRP immunoreactive nerve fibers in rat nasal epithelium (54). These data suggest that exposure of airway epithelium to inhaled irritants can lead to increases in neuropeptide gene transcription and translation within the neuronal cell bodies located in sensory ganglia.

Allergen-induced inflammation of the airways may also stimulate the neuronal synthesis of tachykinins in sensory ganglia. In sensitized guinea pigs, challenge of the nasal mucosa with the sensitizing allergen enhanced the synthesis of substance P and CGRP in the cell bodies of trigeminal ganglion neurons and the axonal transportation of these peptides to their terminals in the nasal mucosa (56). Similarly, within 24 hr of allergen inhalation, there is a 3- to 5-fold elevation in the amount of substance P, NK-A and CGRP immunoreactivity in the lungs of guinea pigs (17). Although decreased enzymatic breakdown of tachykinins within the airways may contribute to this elevation (57), at least a component of the increased content of tachykinins stems from an increase in tachykinin synthesis (17). A somewhat surprising observation was that, following allergen challenge, nodose neurons whose axons projected to the airways were shown to express tachykinins. This was surprising, as nodose fibers that innervate guinea pig airways do not normally contain immunoreactive tachykinins. In sensitized guinea pigs not challenged with antigen, only 1% of cell bodies of airways innervating nodose fibers were immunoreactive for substance P. In challenged guinea pigs, approximately 10% of cell bodies of nodose neurons retrogradely labeled from the airways were immunoreactive for substance P (17). Histologic studies support the hypothesis that allergen inflammation causes a substantive qualitative change in the type of airway afferent fibers that contained tachykinins, such that non-nociceptive (capsaicin-insensitive, low-threshold mechanosensors) as well as nociceptive airway afferent fibers contribute to the neuropeptide innervation (Figure 1) (58). The implications of this qualitative difference are discussed below in the section on enhanced release of tachykinins.

The mechanism by which airway exposure to allergens or inhaled irritants leads to increases in neuropeptide synthesis within cell bodies of remotely located ganglia is unknown. A family of molecules known to act on nerve endings to send growth signals to their cell bodies is the neurotransphins. Neurotrophins [e.g., nerve growth factor (NGF), brain derived neurotrophic factor, neurotrophin 3 and 4] support the survival, differentiation, and function of neurons of the central and peripheral nervous system (59). Inflammation of the airways is associated with increased levels of neurotrophic factors that may stimulate plasticity in afferent innervation. Potential cellular sources for this increase in airway neurotrophins include the respiratory epithelium, T lymphocytes, alveolar macrophages, and mast cells (60–62). Neurotrophins initiate their effects in vagal afferent neurons, in part, by binding to high-affinity receptors of the tyrosine kinase family, followed by uptake and retrograde transport to the cell body in the vagal ganglia (63). Among the family of neurotrophins most attention has been given to NGF as a potential mediator in afferent plasticity in inflamed airways. NGF is found in human airways, and the NGF content of airway lavage fluid is increased following allergen challenge (61,64–66). NGF is capable of regulating the expression of mRNA encoding the precursors of substance P and CGRP in mature afferent neurons (67). Moreover, instillation of NGF into the trachea of guinea pigs was associated with a greater percentage of airway-specific afferent neurons that express immunoreactive substance P and also lead to a qualitative switch in the nature of the nodose afferent neurons (16), results similar to those following allergen challenge. That is, after NGF exposure, non-nociceptive-like (nodose fibers) as well as nociceptive-like (jugular fibers) airway afferent fibers contained tachykinins.

**Enhanced Release of Tachykinins**

The release of tachykinins from the peripheral terminals of C fibers in the airways is thought to occur via an axon reflex. An axon reflex occurs when stimulation of a C fiber ending results in action potentials which, in addition to traveling orthodromically toward the central nervous system, also travel antidromically via collateral branches to effect the release of tachykinins. The release of tachykinins from the peripheral terminals of afferent nerves can be induced by a variety of stimuli including...
capsaicin (68), bradykinin (69), electrical nerve stimulation (70), cigarette smoke (71), low pH (72), and hypertonic saline (73). The release of tachykinins from the peripheral terminals of C fibers in the airways may result in increased blood flow through the microvascular bed of the airways, increased microvascular permeability, inflammatory cell recruitment, stimulation of airways secretions, and airway smooth muscle contraction (74).

There is some evidence to suggest inflammation of the airways can enhance the release of tachykinins from the peripheral terminals of vagal afferent neurons. In guinea pig isolated airway preparations, specific allergen, at a concentration that caused only a threshold level of mediator release, profoundly elevated tachykinergic nerve-mediated contraction of airways smooth muscle (70). This was independent of tachykinin synthesis (the cell bodies were removed); however, it was mimicked by histamine. Moreover, the histamine H1 receptor-selective antagonist pyrilamine could prevent and reverse the antigen-induced potentiation. Other mast cell mediators such as the cysteinyi leukotrienes (Cys-LTs) may also contribute to allergen-induced potentiation of tachykinergic nerve-mediated responses.

Inflammation is known to induce a similar qualitative change in "touch fibers" of the somato-sensory system so they, like nociceptive C fibers, express substance P. Substance P released from the central terminals of these touch fibers appears to contribute to inflammatory hyperalgesia by enhancing transmission in the spinal cord and exaggerating the central response to normally innocuous stimuli (87). It is reasonable to speculate that the release of tachykinins from non-nociceptive afferent neurons that innervate the airways will influence the excitability of synaptic transmission in the central nervous system, such that the enhancement of these mechanically sensitive neurons may lead to exaggerated reflex responses to innocuous stimuli.

**Figure 3.** Histogram showing the effect of a 75 µg/kg dose of capsaicin (closed columns) or vehicle (open columns) on vascular permeability in the tracheas of 5 groups of rats: pathogen free, pathogen free with 4 weeks of NH3 exposure, 6 days after inoculation with M. pulmonis, and 4 weeks after inoculation with M. pulmonis with continuous NH3 exposure. Vascular permeability was assessed using Monastral blue as a tracer. Values are mean ± SE (n = 3–7) of the amounts of Monastral blue pigment, expressed as area densities (percentage of mucosal surface area in which labeled blood vessels are present). Figure reprinted from M. Condon (77) with permission of American Lung Association.

**Conclusions**

Various anatomic and physiologic properties of airway afferent neurons change in response to irritation and inflammation in the airways. Perhaps one of the more dramatic changes that occurs is the induction of NK synthesis in airways afferent fibers that under normal conditions do not normally contain neurokinins. As neurokinin release in the brain stem may enhance airway reflexes, stimuli leading to the qualitative change in the type of airway afferent producing and releasing tachykinins like that seen following allergen challenge may contribute to the symptoms of airway inflammation. Thus it may be that in inflamed airways, it is not only that there is more neurokinin in the nerves innervating the airways, but also that the nerves that are more easily activated (non-nociceptive fibers) now contain and release neurokinins. Inflammation is known to induce a similar qualitative switch in "touch fibers" of the somato-sensory system so they, like nociceptive C fibers, express substance P. Substance P released from the central terminals of these touch fibers appears to contribute to inflammatory hyperalgesia by enhancing transmission in the spinal cord and exaggerating the central response to normally innocuous stimuli (87). It is reasonable to speculate that the release of tachykinins from non-nociceptive afferent neurons that innervate the airways will influence the excitability of synaptic transmission in the central nervous system, such that the enhancement of these mechanically sensitive neurons may lead to exaggerated reflex responses to innocuous stimuli.

**References and Notes**

1. Gallezat M, Garry MG, Yost HJ, Strati KA, Hargreaves KM, Seybold VS. Plasticity in the synthesis and storage of substance P and calcitonin gene-related peptide in primary afferent neurons during peripheral inflammation. Neuroscience 66:443–458 (1995).

2. Sheehy KA. Substance P and calcitonin gene-related peptide (CGRP) in gastrointestinal inflammation. Ann N Y Acad Sci 664:425–442 (1992).

3. Stead RH. Neuropeptides during intestinal inflammation. Ann N Y Acad Sci 664:443–455 (1992).

4. Wolf CJ, Sailer MW. Neuronal plasticity: increasing the gain in pain. Science 288:1765–1769 (2000).

5. M-Carrion SE, Kallman BM. Novel classes of nociceptors: beyond Sherrington. Trends Neurosci 13:199–201 (1990).

6. Coleridge J, Coleridge HM. Afferent vagal C fiber innervation of the lungs and airways and its functional significance. Rev Physiol Biochem Pharmacol 99:1–110 (1984).

7. Coleridge HM, Coleridge JC, Schultz MD. Afferent pathways involved in reflex regulation of airway smooth muscle. Pharmacol Ther 42:1–63 (1988).

8. Coleridge HM, Coleridge GC. Afferent nerves in the airways. In: Autonomic Control of the Respiratory System (Barnes PJ, ed). Amsterdam:Harwood, 1997:39–58.

9. Undem BJ, Riccio MM. Activation of airway afferent nerves. In: Asthma (Barnes PJ, Gineste MF, Leff AR, Woolcock AJ, eds). Philadelphia: Lippincott-Raven, 1997:1009–1025.

10. Anggard A, Lundberg JM, Lundblad L. Nasal sympathetic innervation of guinea-pig lung and trachea as studied by retrograde neuronal tracing and double-labelling immunohistochemistry. Neurosci/Lett 48:337–341 (1990).

11. Kerr, W., Fischer A, Kurkowski R, Heym C. The sensory and sympathetic innervation of guinea-pig lung and trachea as studied by retrograde neuronal tracing and double-labeling immunohistochemistry. Neurosci/Lett 48:337–341 (1990).

12. Sarria A, Martling CR, Dalsgaard CJ, Lundberg JM. Evidence for substance P-immunoreactive spiral afferents that mediate bronchoconstriction. Am J Physiol 251:L197–204 (1986).

13. Riccio MM, Kummer W, Bigliari B, Myers AC, Undem BJ. Interganglionic segregation of distinct vagal afferent fibres in the airways of guinea-pig. J Physiol (Lond 496:521–530 (1996).

14. Solway J, Leff AR. Sensory neuropeptides and airway function. J Appl Physiol 70:2077–2087 (1991).

15. Hunter DD, Myers AC, Undem BJ. Neural growth-factor-induced phenotypic switch in guinea pig airway sensory neurons. Am J Respir Crit Care Med 161:1985–1990 (2000).

16. Fischer A, M-Gregor GP, Sarria A, Phillipson B, Kummer W. Induction of tachykinin gene and peptide expression in guinea
pig noseode primary afferent neurons by allergic airway inflammation. J Clin Invest 98:2828–2921 (1996).

18. Schill HG, MEZ˘
C. Effects of mechanical stimuli on afferent activity in patients with allergic rhinitis. J Neuroimmunol 60:210–219 (1995).

19. Nadel JA. Effects of an experimental arthritis on the sensory properties of fine afferent nerve fibers. J Neuroimmunol 54:1108–1122 (1995).

20. Habler HJ, Janig W, Koltzenburg M. Activation of unmyelinated nerve fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. J Physiol (Lond) 425:545–562 (1989).

21. Sanico AM, Kolasinski ST, Stanis AM, Bieniek J, Topias A. Hyperalgesia and nerve growth factor in allergic rhinitis. Int Arch Allergy Immunol 118:154–158 (1999).

22. Holtzman MJ, Sheller JR, Dimeo M, Nadel JA, Boushey HA. Variable inhibition of histamine-induced bronchoconstriction in patients with symptomatic allergy is mediated by neural factors. J Allergy Clin Immunol 97:2522–2526 (1996).

23. Adcock J, Garland GD. The contribution of sensory nerves and “hyperalgesia” to airway hyperresponsiveness. In: Airway Hyperresponsiveness—Is It Really Important for Asthma? (Page CP, Gardiner P, eds), Blackwell Scientific Press, 1993:236-245.

24. Holtzman MJ, Sheller JR, Dimeo M, Nadel JA, Boushey HA. Effects of ganglionic blockade on bronchial reactivity in asthmatic subjects. Am Rev Respir Dis 122:17-25 (1980).

25. Sheppard D, Epstein J, Skoogh BE, Bethel RA, Nadel JA, Hennig S. Mechanosensitivity and time course of mechanosensitivity changes in articular afferents during a developing experimental arthritis. J Rheumatol 13:131–139 (1986).

26. Schaible HG, Schmidt RF. Time course of mechanosensitivity changes in articular afferents during a developing experimental arthritis. J Neurophysiol 60:1711–1720 (1988).

27. Fuller RW, Dixon CM, Barnes PJ. Bradykinin-induced bronchoconstriction in atopic subjects. J Allergy Clin Immunol 97:2522–2526 (1996).

28. Peat JN, Argyle M, Helliwell S, Eiser J, Nadel JA. Activation of unmyelinated nerve fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. J Physiol (Lond) 425:545–562 (1989).

29. Minette PA, Lammers JW, Dixon CM, McCusker MT, Barnes PJ. Bronchial hyperresponsiveness in normal subjects during attenuation of nasal vaccination with a homologous vaccine. Am Rev Respir Dis 135:176–180 (1987).

30. Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Sato A, Takahashi N. Bronchial hyperresponsiveness induced by inhaled histamine in normal and asthmatic subjects. Thorax 55:357–362 (2000).

31. Holt MM, Bai TR, Shore SA, Hall AE, Drzen J. Neuropeptide content of lungs from asthmatic and nonasthmatic patients. Am Rev Respir Dis 157:1595–1596 (1998).

32. Olearner SL, Janis DJ, Sisson CE, Woolf CJ. Substance P and neuropeptide immunoreactivity in lungs from asthmatics and nonasthmatics. Eur Respir J 4:37–42 (1991).

33. Fujishima H, Takeyama M, Takeuchi T, Saito I, Tsubota K. Bronchial hyperresponsiveness in normal subjects during attenuation of nasal vaccination with a homologous vaccine. Am Rev Respir Dis 135:176–180 (1987).

34. Carr MJ, Undem BJ. Ion channels in airway afferent neurons. J Physiol (Lond) 492:499–509 (1996).

35. Empey DW, Laitinen LA, Jacobs L, Gold WM, Nadel JA. Bronchial hyperresponsiveness in normal subjects following acute and chronic upper respiratory tract infection. Am Rev Respir Dis 122:3–10 (1980).

36. Takeda N, Kalubi B, Abe Y, Irifune M, Ogino S, Matsunaga T. Bronchial hyperresponsiveness in normal subjects during attenuation of nasal vaccination with a homologous vaccine. Am Rev Respir Dis 135:176–180 (1987).

37. Riccio MM, Myers AC, Undem BJ. Immunomodulation of afferent nerves in normal human airways. Am Rev Respir Dis 137:1321–1328 (1988).

38. Carr MJ, Undem BJ. Ion channels in airway afferent neurons. J Physiol (Lond) 492:499–509 (1996).

39. Keranen U, Kiluluo T, Järvensalo H, Back N, Kiihkkola E, Soinila S. Changes in substance P-immunoreactive innervation of human colon associated with ulcerative colitis. Dig Dis Sci 40:2250–2258 (1995).

40. McAlexander MA, Myers AC, Undem BJ. Inhibition of 5-lipoxygenase products of arachidonic acid metabolism by substance P in normal and asthmatic human airway. J Allergy Clin Immunol 90:646–652 (1992).

41. Collins SM. The immunomodulation of enteric neuromuscular activity and late asthmatic reactions. J Clin Investig 83:1–10 (1989).

42. Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. Bronchial hyperresponsiveness induced by inhaled histamine in normal and asthmatic subjects. Thorax 55:357–362 (2000).

43. McCusker MT, Barnes PJ, Undem BJ, Hourihane J, Nadel JA. Bronchial hyperresponsiveness induced by inhaled histamine in normal and asthmatic subjects. Thorax 55:357–362 (2000).

44. Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Sato A, Takahashi N. Bronchial hyperresponsiveness induced by inhaled histamine in normal and asthmatic subjects. Thorax 55:357–362 (2000).

45. Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Sato A, Takahashi N. Bronchial hyperresponsiveness induced by inhaled histamine in normal and asthmatic subjects. Thorax 55:357–362 (2000).

46. Empey DW, Laitinen LA, Jacobs L, Gold WM, Nadel JA. Mechanosensitive and thermal hyperalgesia in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 138:1311–1319 (1989).

47. Cort E, Holgate ST. Mechanisms of airway hyperactivity. J Allergy Clin Immunol 113:131–137 (2004).

48. LeSouëf PN, Mann SE, Kaljurand K, Braden R, Bischof C, Tschopp M, et al. Hyperalgesia and nerve growth factor in allergic rhinitis. J Physiol (Lond) 491:499–509 (1996).

49. Carr MJ, Undem BJ. Ion channels in airway afferent neurons. Respir Physiol 125:83–97 (2001).

50. Painiat AS. Mechanism of stimulation of type J pulmonary receptors. J Physiol (Lond) 203:511–527 (1969).

51. Fujishima H, Takeuchi M, Takeuchi T, Saito I, Tsuoboto K. Elevated levels of substance P in tears of patients with allergic conjunctivitis and varicella conjunctivitis. Clin Exp Allergy 27:372–378 (1997).

52. Collins SM. The immunomodulation of enteric neuromuscular function: Implications for motility and inflammatory disorders. Gastroenterology 121:1882–1899 (2001).

53. Wolff CJ, Sahne-Garabedian B, M & QP, Crilly P, Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62:327–333 (1994).

54. Sheppard D, Epstein J, Skoogh BE, Bethel RA, Nadel JA, Hennig S. Mechanosensitivity and time course of mechanosensitivity changes in articular afferents during a developing experimental arthritis. J Neuroimmunol 60:210–219 (1995).

55. Nadel JA. Activation of unmyelinated nerve fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. J Physiol (Lond) 425:545–562 (1989).

56. Sanico AM, Kolasinski ST, Stanis AM, Bieniek J, Topias A. Hyperalgesia and nerve growth factor in allergic rhinitis. Int Arch Allergy Immunol 118:154–158 (1999).

57. Holtzman MJ, Sheller JR, Dimeo M, Nadel JA, Boushey HA. Variable inhibition of histamine-induced bronchoconstriction in patients with symptomatic allergy is mediated by neural factors. J Allergy Clin Immunol 97:2522–2526 (1996).

58. Adcock J, Garland GD. The contribution of sensory nerves and “hyperalgesia” to airway hyperresponsiveness. In: Airway Hyperresponsiveness—Is It Really Important for Asthma? (Page CP, Gardiner P, eds), Blackwell Scientific Press, 1993:236-245.